Evidence map›Paper›PMID 37208616›Full record

ArticleBMC gastroenterology2023

Clinical epidemiology and outcomes of patients with gastric intestinal metaplasia in the Los Angeles County System.

Preeti Prakash, Shailavi Jain, Harry Trieu, Kenneth Chow, Deepthi Karunasiri, Tom Liang, Evan Yung, Holli Mason, Hongying Tan, James H Tabibian

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Preeti PrakashDavid Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA. paprakash@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-5037-7066
Shailavi JainDavid Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Harry TrieuKeck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
Kenneth ChowDepartment of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA.
Deepthi KarunasiriDepartment of Pathology, Olive-View-UCLA Medical Center, Sylmar, CA, USA.
Tom LiangDepartment of Pathology, Los Angeles County-University of Southern California Medical Center, Los Angeles, CA, USA.
Evan YungDepartment of Pathology, Los Angeles County-University of Southern California Medical Center, Los Angeles, CA, USA.
Holli MasonDepartment of Pathology, Harbor-UCLA Medical Center, Torrance, CA, USA.
Hongying TanDepartment of Pathology, Olive-View-UCLA Medical Center, Sylmar, CA, USA.
James H TabibianDavid Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA.
University of Southern California · USOlive View-UCLA Medical Center · USUCLA Medical Center · USUniversity of California, Los Angeles · USBoston University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric intestinal metaplasia (GIM) is a precursor to gastric adenocarcinoma (GAC). In the United States, there is no consensus on the utility of surveillance for GIM, and minority populations most affected by GAC are understudied. Our aims were to define clinical and endoscopic features, surveillance practices, and outcomes in patients with GIM in a multicenter safety-net system.

methodsWe identified patients with biopsy-proven GIM between 2016-2020 at the three medical centers comprising Los Angeles County Department of Health Services. Demographics, findings at index esophagogastroduodenoscopy (EGD) first showing GIM, recommended interval for repeat EGD, and findings at repeat EGD were abstracted. Descriptive statistics were performed to characterize our cohort. T-tests and chi-squared (χ

resultsThere were 342 patients with newly-diagnosed biopsy-proven GIM, 18 (5.2%) of whom had GAC at index EGD. Hispanic patients comprised 71.8% of patients. For most patients (59%), repeat EGD was not recommended. If recommended, 2-3 years was the most common interval. During a median time to repeat EGD of 13 months and cumulative follow-up of 119 patient-years, 29.5% of patients underwent at least one repeat EGD, of whom 14% had multifocal GIM not previously detected. Progression to dysplasia or GAC was not detected in any patients.

conclusionIn a predominantly minority population with biopsy-proven GIM, there was a 5% incidence of GAC on index EGD. Though progression to neither dysplasia nor GAC was detected, there was significant variability in endoscopic sampling and surveillance practices.

Indexed as

Precancerous ConditionsStomach NeoplasmsBiopsyEndoscopyHumansHyperplasiaLos AngelesMetaplasiaDisparities, HealthcareEndoscopyGastric cancerRisk FactorsSurveillance

Identifiers

PMID37208616
PMCPMC10197307
OpenAlexW4377096998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.